Beuers, Ulrich

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 3,476

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 3,100

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.

Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 1,480

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 1,131

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,035

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2024) · Annals of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 844

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

Paumgartner, G., & Beuers, U. (2002) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 748

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis: Boonstra et al.

Boonstra, K., Weersma, R. K., van Erpecum, K. J., Rauws, E. A., Spanier, B. W. M., Poen, A. C., van Nieuwkerk, K. M., Drenth, J. P., Witteman, B. J., Tuynman, H. A., et al. (2013) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 725

Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review

Boonstra, K., Beuers, U., & Ponsioen, C. Y. (2012) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 632

New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond

Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology

Drug Transport and Resistance MechanismsLiver Diseases and Immunity

Cited by 537

Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis

Weismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 533

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

Beuers, U., Spengler, U., Kruis, W., Aydemir, Ü., Wiebecke, B., Heldwein, W., Weinzierl, M., Pape, G. R., Sauerbruch, T., & Paumgartner, G. (1992) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 448

EASL Clinical Practice Guidelines on sclerosing cholangitis

Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 419

Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis

Beuers, U. (2006) · Nature Clinical Practice Gastroenterology & Hepatology

Drug Transport and Resistance MechanismsLiver Diseases and Immunity

Cited by 417

Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus

Kremer, A. E., Martens, J. J. W. W., Kulik, W., Ruëff, F., Kuiper, E. M. M., van Buuren, H. R., van Erpecum, K. J., Kondrackiene, J., Prieto, J., Rust, C., et al. (2010) · Gastroenterology

Dermatology and Skin DiseasesLiver Diseases and Immunity

Cited by 410

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

The UK-PSC Consortium, Ji, S.-G., The International IBD Genetics Consortium, The International PSC Study Group, Juran, B. D., Mucha, S., Folseraas, T., Jostins, L., Melum, E., Kumasaka, N., et al. (2017) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 357

The Biliary HCO3 − Umbrella: A Unifying Hypothesis on Pathogenetic and Therapeutic Aspects of Fibrosing Cholangiopathies

Beuers, U., Hohenester, S., de Buy Wenniger, L. J. M., Kremer, A. E., Jansen, P. L. M., & Elferink, R. P. J. O. (2010) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 351

A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes

Hohenester, S., de Buy Wenniger, L. M., Paulusma, C. C., van Vliet, S. J., Jefferson, D. M., Oude Elferink, R. P., & Beuers, U. (2012) · Hepatology

Drug Transport and Resistance MechanismsLiver Diseases and Immunity

Cited by 315

Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1

de Boer, Y. S., van Gerven, N. M. F., Zwiers, A., Verwer, B. J., van Hoek, B., van Erpecum, K. J., Beuers, U., van Buuren, H. R., Drenth, J. P. H., den Ouden, J. W., et al. (2014) · Gastroenterology

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 304

Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions

Kremer, A. E., van Dijk, R., Leckie, P., Schaap, F. G., Kuiper, E. M. M., Mettang, T., Reiners, K. S., Raap, U., van Buuren, H. R., van Erpecum, K. J., et al. (2012) · Hepatology

Liver Diseases and ImmunityDermatology and Skin Diseases

Cited by 291

European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations

Löhr, J., Beuers, U., Vujasinovic, M., Alvaro, D., Frøkjær, J. B., Buttgereit, F., Capurso, G., Culver, E. L., de‐Madaria, E., Della‐Torre, E., et al. (2020) · United European Gastroenterology Journal

IgG4-Related and Inflammatory DiseasesPancreatitis Pathology and Treatment

Cited by 252

Efficacy and Safety of Ursodeoxycholic Acid Versus Cholestyramine in Intrahepatic Cholestasis of Pregnancy

Kondrackiene, J., Beuers, U., & Kupcinskas, L. (2005) · Gastroenterology

Pregnancy and Medication ImpactLiver Diseases and Immunity

Cited by 247

Pruritus in cholestasis: facts and fiction

Beuers, U., Kremer, A. E., Bolier, R., & Elferink, R. P. J. O. (2014) · Hepatology

Liver Diseases and ImmunityDermatology and Skin Diseases

Cited by 225

Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial

de Vries, E., Bolier, R., Goet, J., Parés, A., Verbeek, J., de Vree, M., Drenth, J., van Erpecum, K., van Nieuwkerk, K., van der Heide, F., et al. (2021) · Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 224